Clinical trials: Perennial Allergic Rhinitis (PAR)
Hay Fever, Perennial Allergic Rhinitis
Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)
The purpose of this study is to evaluate the safety and tolerability of ciclesonide nasal spray for long term use in relieving symptoms in perennial allergic rhinitis.
- Trial name
- NCT00261287
- Testing
- Ciclesonide
- Where
- 3 sites in United States
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
Rhinitis, Allergic, Perennial
Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)
The purpose of the study is to assess the efficacy and safety of an investigational nasal aerosol compared with placebo nasal aerosol in the treatment of perennial allergic rhinitis.
- Trial name
- NCT01134705
- Testing
- Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol
- Where
- 35 sites in United States
- Volunteers
- 474 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Rhinitis Allergic
A Study to Assess Efficacy and Safety of Nasacort® Nasal Spray in Comparison With Flixonase® Nasal Spray in Adults Suffering From Perennial Allergic Rhinitis (PAR)
Primary Objective: To assess efficacy of Nasacort® (triamcinolone) nasal spray, 55 µg per dose, in comparison with Flixonase® (fluticasone) nasal spray, 50 µg per dose, by reflective total nasal symptom score (rTNSS) (24 h) after…
- Trial name
- NASANIF (NCT03317015)
- Testing
- triamcinolone XRG5029, fluticasone
- Volunteers
- 260 people
- Sponsor
- Sanofi
Rhinitis, Allergic, Perennial
A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR).
The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with…
- Trial name
- NCT00103454
- Testing
- GW685698X
- Where
- 49 sites in United States, Canada
- Volunteers
- 288 people
- Sponsor
- GlaxoSmithKline
Rhinitis, Allergic, Perennial
Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)
The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with…
- Trial name
- NCT00289198
- Testing
- FF
- Where
- 42 sites in United States, Australia and 7 more
- Volunteers
- 301 people
- Sponsor
- GlaxoSmithKline
Perennial Allergic Rhinitis
Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray
This is a randomized, multicenter, 2-way crossover study in subjects 12 years or older with perennial allergic rhinitis (PAR) to evaluate patient preference, satisfaction and efficacy of ciclesonide nasal aerosol versus…
- Trial name
- NCT01401465
- Testing
- ciclesonide, mometasone
- Where
- 15 sites in United States
- Volunteers
- 327 people
- Sponsor
- Sumitomo Pharma America, Inc.
Perennial Allergic Rhinitis, Allergic Rhinitis
Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)
The purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal spray as compared with placebo (inactive substance) nasal spray in relieving symptoms of perennial allergic rhinitis.
- Conditions
- Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
- Trial name
- NCT00163514
- Testing
- Ciclesonide
- Where
- 74 sites in United States, Canada
- Volunteers
- 636 people
- Sponsor
- AstraZeneca
Perennial Allergic Rhinitis, PAR
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of ciclesonide nasal aerosol administered once daily to male and premenarchal female subjects 6 to 11 years…
- Trial name
- NCT01451541
- Testing
- Ciclesonide nasal aerosol 37 mcg, ciclesonide nasal aerosol 74 mcg
- Where
- 60 sites in United States
- Volunteers
- 848 people
- Sponsor
- Sumitomo Pharma America, Inc.
Rhinitis Perennial
Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Perennial Allergic Rhinitis (PAR)
Primary Objective: To evaluate safety (4 weeks) Secondary Objectives: To evaluate the long-term safety (12 weeks) To evaluate the efficacy To characterize the pharmacokinetic profile
- Trial name
- NCT01244217
- Testing
- fexofenadine/Allegra (M016455)
- Where
- 15 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Sanofi
Perennial Allergic Rhinitis (PAR)
Study of CM512 Injection in Patients With Perennial Allergic Rhinitis on Background Therapy
This is a randomized, double-blind, placebo-parallel controlled phase II study to evaluate the safety and efficacy of CM512 in patients with perennial allergic rhinitis on background therapy
- Trial name
- NCT07890350
- Testing
- CM512
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Beijing Keymed Biosciences Co., Ltd.
Rhinitis, Allergic, Perennial
To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)
The primary objective of this study is to demonstrate the efficacy of ciclesonide applied as a nasal spray once daily in patients with PAR. The secondary objectives are to evaluate Quality-of-Life and safety.
- Trial name
- NCT00659750
- Testing
- Ciclesonide
- Where
- 23 sites in United States
- Volunteers
- 418 people
- Sponsor
- AstraZeneca
Rhinitis, Allergic, Perennial
A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis
Allergic rhinitis is an IgE-mediated, inflammatory disorder of the upper airway that occurs following allergen exposure. Perennial Allergic Rhinitis (PAR) starts in early childhood and occurs all year around.
- Trial name
- AVY-REG00108VN (NCT01270958)
- Testing
- Avamys aqueous nasal spray 110mcg
- Where
- Vietnam
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Perennial Allergic Rhinitis
Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis
This is an open-label, randomized, multicenter, 2-way crossover study in subjects 12 years or older with perennial allergic rhinitis (PAR) to evaluate the psychometric properties of a novel-patient administered assessment of…
- Trial name
- NCT01287364
- Testing
- ciclesonide hydrofluoroalkane (HFA) nasal aerosol, mometasone nasal inhalation
- Where
- 6 sites in United States
- Volunteers
- 185 people
- Sponsor
- Sumitomo Pharma America, Inc.
Perennial Allergic Rhinitis (PAR)
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. Participants can expect study participation to last up to 29.5 months.
- Trial name
- NCT06339008
- Testing
- LY3650150, Standard therapy for INCS
- Where
- 74 sites in United States, Belgium and 4 more
- Volunteers
- 450 people
- Sponsor
- Eli Lilly and Company
Perennial Allergic Rhinitis
Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)
To evaluate the long term safety and efficacy of GSP 301 NS compared to 2 placebo NS formulations for the treatment of perennial allergic rhinitis (subjects 12 years of age and older)
- Trial name
- GSP 301-303 (NCT02709538)
- Testing
- GSP 301 NS
- Where
- 34 sites in United States
- Volunteers
- 601 people
- Sponsor
- Glenmark Specialty S.A.
Perennial Allergic Rhinitis, Allergic Rhinitis
Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)
The purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal spray as compared with placebo (inactive substance) nasal spray in relieving symptoms of perennial allergic rhinitis.
- Conditions
- Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
- Trial name
- NCT00163501
- Testing
- Ciclesonide
- Where
- 41 sites in United States
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Perennial Allergic Rhinitis
Children, Perennial Allergic Rhinitis (PAR), l-t Growth
The purpose of this study is to compare the effect of Rhinocort nasal spray with placebo on growth in children with perennial allergic rhinitis over 12 months.
- Trial name
- NCT00641212
- Testing
- Budesonide
- Volunteers
- 209 people
- Sponsor
- AstraZeneca
Perennial Allergic Rhinitis
Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)
The purpose of the study is to evaluate the effects of BDP HFA Nasal Aerosol on HPA-axis function.
- Trial name
- NCT01133626
- Testing
- Prednisone capsules, Beclomethasone dipropionate
- Where
- 3 sites in United States
- Volunteers
- 107 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Perennial Allergic Rhinitis, PAR
Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, safety study of the effects of ciclesonide nasal aerosol (74 mcg) on the HPA axis when administered once daily to male and premenarchal female…
- Trial name
- NCT01378429
- Testing
- ciclesonide nasal aerosol
- Where
- 7 sites in United States
- Volunteers
- 89 people
- Sponsor
- Sumitomo Pharma America, Inc.
Perennial Allergic Rhinitis (PAR)
Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis
This study will be a prospective observational study of "real world" BDP nasal aerosol users with PAR, with or without seasonal allergic rhinitis (SAR).
- Trial name
- BALANCE (NCT01632540)
- Testing
- Beclomethasone Dipropionate (BDP) Nasal Aerosol
- Where
- 46 sites in United States
- Volunteers
- 824 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.